Limula

Problem: The biopharma industry faces significant challenges in transforming highly personalized treatments into scalable, commercially viable solutions. Cell therapy, for example, costs over €500,000 per dose due to labor-intensive manufacturing processes, complex equipment, and expensive infrastructure. As a result, only 2% of eligible patients benefit from these treatments, highlighting the urgent need for scalable and cost-effective solutions. Solution: Our fully automated cell therapy manufacturing platform enables scalable production of cell therapies. Limula integrates expertise in process development with "Swiss Made" precision engineering to deliver end-to-end manufacturing within a single device. This innovation has the potential to dramatically reduce costs and unlock a high-growth market for our customers. Target Markets: Hospitals, Biotech Companies, Pharma Companies, CDMO Looking for business opportunities in: Business Expertise, Market Access, Investor, Corporation Technology Readiness Level: TRL 6-7 Minimum Viable Product Contact info: Luc Henry info@limula.ch